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Abstract
Background: Erythroid development requires the action of erythropoietin (EPO) on committed progenitors to match red
cell output to demand. In this process, iron acts as a critical cofactor, with iron deficiency blunting EPO-responsiveness of
erythroid progenitors. Aconitase enzymes have recently been identified as possible signal integration elements that couple
erythropoiesis with iron availability. In the current study, a regulatory role for aconitase during erythropoiesis was
ascertained using a direct inhibitory strategy.
Methodology/Principal Findings: In C57BL/6 mice, infusion of an aconitase active-site inhibitor caused a hypoplastic
anemia and suppressed responsiveness to hemolytic challenge. In a murine model of polycythemia vera, aconitase
inhibition rapidly normalized red cell counts, but did not perturb other lineages. In primary erythroid progenitor cultures,
aconitase inhibition impaired proliferation and maturation but had no effect on viability or ATP levels. This inhibition
correlated with a blockade in EPO signal transmission specifically via ERK, with preservation of JAK2-STAT5 and Akt
activation. Correspondingly, a physical interaction between ERK and mitochondrial aconitase was identified and found to be
sensitive to aconitase inhibition.
Conclusions/Significance: Direct aconitase inhibition interferes with erythropoiesis in vivo and in vitro, confirming a
lineage-selective regulatory role involving its enzymatic activity. This inhibition spares metabolic function but impedes EPO-
induced ERK signaling and disturbs a newly identified ERK-aconitase physical interaction. We propose a model in which
aconitase functions as a licensing factor in ERK-dependent proliferation and differentiation, thereby providing a regulatory
input for iron in EPO-dependent erythropoiesis. Directly targeting aconitase may provide an alternative to phlebotomy in
the treatment of polycythemia vera.
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Introduction
Production of red blood cells, or erythropoiesis, is regulated by
the cytokine erythropoietin (EPO) in conjunction with iron. In the
context of an adequate iron supply, EPO promotes proliferation,
differentiation, and survival of erythroid progenitors, beginning at
the colony forming unit-erythroid (CFU-E) stage. Iron restriction,
i.e. diminished amounts of bio-available iron, results in diminished
red cell production due to decreased erythroid proliferation and
maturation [1]. Iron regulation of erythropoiesis has been
documented in many experimental models including rats, where
iron deficiency causes a defect in the transition from the CFU-E
stage to the proerythroblast stage [2]. Iron modulation of EPO
bioactivity occurs clinically in patients whose response to
recombinant EPO can be augmented by exogenous iron despite
adequate iron stores [3]. Thus, iron sensing mechanisms in the
erythroid compartment function in a rheostatic manner to adjust
output based on iron availability.
Aconitase enzymes have recently been identified as mediators of
the erythroid response to iron restriction [4]. In mammals,
aconitases consist of mitochondrial and cytosolic isoenzymes that
both utilize a prosthetic 4Fe-4S cubane iron-sulfur cluster group at
their active site to interconvert the metabolites citrate and isocitrate
[5]. They are highly sensitive to intracellular iron levels and redox
conditions. Cellular iron deprivation causes loss of the a-Fe
2+ group
from the iron-sulfur cluster, while oxidative stress induces complete
cluster disassembly, both of which conditions inactivate enzymatic
function[6,7].An additional levelof enzymaticregulationmayarise
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functions through interaction with nucleic acid targets. Cytosolic
aconitase, in its role as Iron Regulatory Protein 1 (IRP1), binds iron
response elements within mRNA sequences of a cohort of iron
responsive genes and regulates their expression [10]. Mitochondrial
aconitase contributes to the protein complexes assembled with the
mitochondrial genome and participates in mitochondrial DNA
maintenance [11].
EPO engagement of its receptor activates the associated cytosolic
tyrosine kinase JAK2, which in turn activates multiple signal
transduction pathways critical in erythropoiesis. One such pathway
consists of RAF-MEK-ERK [12–14]. In many cell types, ERK
activation exerts both positive and negative effects on proliferation
and differentiation, with signal output determined by kinetics and
magnitude of activation, subcellular localization, scaffolds, and
crosstalk with other signaling modules [15]. Known subcellular
locationsforERKincludetheplasmamembrane,endosomes,Golgi
apparatus, nucleus, and mitochondria [16–20]. With regard to
erythropoiesis, enforced ERK activation by mutant N-Ras V12
expression in ex vivo murine fetal liver erythroblast cultures blocked
differentiation and promoted proliferation [21]. In vivo studies also
suggest that ERK1 signaling negatively regulates red cell produc-
tion. In these studies, ERK1 null mice displayed a higher basal rate
of splenic erythropoiesis and responded more rapidly to hemolytic
challenge [22]. On the other hand, MEK inhibition strongly
diminished the yield of erythroid colonies from wild type murine
marrow cultured in the presence of EPO [23]. Thus, as with many
cell types, ERK signaling exerts both positive and negative effects
during erythropoiesis.
Iron regulation of erythropoiesis appears to involve aconitase-
mediated alterations in EPO signal transduction and cellular
metabolism [4]. Because iron deprivation affects numerous cellular
pathways in addition to aconitase, the current studies have
employed a targeted inhibitory approach to more specifically
define the role of aconitase activity in erythropoiesis. These
studies, using a potent active-site inhibitor, revealed that aconitase
activity regulates in vivo steady-state erythropoiesis, as well as
responsiveness to acute anemia. Ex vivo studies confirmed this
regulatory relationship, with aconitase inhibition affecting prolif-
eration and differentiation but not viability. Surprisingly, doses of
the aconitase inhibitor that effectively inhibited erythropoiesis had
no effects on cellular ATP levels or on EPO induction of JAK2
activation but did block ERK-mediated phosphorylation of RSK
substrates. A physical interaction between aconitase and ERK was
observed and found to be sensitive to the inhibitor.
As a putative mediator of the erythroid response to iron restriction,
aconitaseactivity could offer a target for controlling disease inpatients
with polycythemia vera (PV).PVis a hematopoieticstem cell disorder
associated with an activating mutation in JAK2 [24,25] that causes
expansion of red cell mass and possible thrombotic and hemorrhagic
complications [26]. The treatment of choice for normalizing red cell
mass has consisted of induction of iron deficiency through repeated
phlebotomy. In this study, low-dose infusion of the aconitase inhibitor
rapidlynormalized redcellcountsina murine modelof PV.Thusthe
novel pathway for aconitase regulation of erythropoiesis described
herein bears potential for therapeutic manipulation in the setting of
oncogenic signaling.
Results
Induction of anemia by the aconitase inhibitor
fluoroacetate
Aconitase enzymes have recently been implicated in the
erythroid iron restriction response in ex vivo progenitor cultures
and in iron deficient mice [4]. To define the contribution of
aconitase enzymatic activity to erythropoiesis in vivo, the potent
and specific active-site inhibitor of aconitase fluoroacetate (FA) was
administered to mice [27]. Previous studies have shown that FA
can be safely administered to mice at a dose of 4 mg/kg/day using
a continuous infusion pump, a regimen that causes a 60% increase
in resting serum citrate levels [28]. Accordingly, an infusion of FA
or 0.9% saline was delivered to C57BL/6 mice at this dosing rate
[28]. Complete blood counts obtained after 14 days revealed
anemia in the FA-treated animals compared with controls
(Table 1). In particular, red blood cell (RBC) counts, hemoglobin
and hematocrit were significantly decreased in the FA-treated
group. Importantly, the mean corpuscular hemoglobin concen-
tration (MCHC) was unaffected by aconitase inhibition (Table 1),
in contrast to the hypochromic anemias associated with defective
heme biosynthesis (see Discussion). With regard to non-erythroid
cells, FA treatment at 4 mg/kg/day caused a slight decrease in
absolute neutrophil counts (ANC) and did not affect platelets
(Table 1). The inhibition of the ANC was not reproducible in
subsequent experiments. By contrast, the erythroid abnormalities
associated with FA infusion were highly reproducible in multiple
experiments; even those using a 2 mg/kg/day dosing regimen (see
Table S1). To confirm that FA treatment inhibited aconitase
activity in vivo, serum citrate levels were measured, and the 2 mg/
kg/day dosing regimen was found to cause a 1.9-fold increase in
mean serum citrate concentration (Fig. S1).
Further characterization revealed the anemia to be associated
with a 2.5-fold increase in serum EPO levels (Fig. 1A) and a
significant decrease in absolute reticulocyte counts (Fig. 1B). Flow
cytometric analysis of bone marrow erythroid maturation
employed co-staining for CD71 and Ter119, as has been described
(Fig. 1C) [29]. The FA-treated mice showed a significant increase
in frequency and absolute number of R3 erythroid precursors
(CD71
Intermediate Ter119
Bright) (Figs. 1C–E). This defect in
erythroid maturation was observed in multiple independent
experiments involving in vivo aconitase inhibition. Maturation
was also analyzed using a recently described approach that
resolves Ter119
+ erythroid precursors into five distinct subpopu-
lations based on CD44 levels and forward scatter (FSC) [30]. This
approach showed a significant increase in the frequency of CD44
2
FSC
Low cells (stage V) associated with FA treatment (Fig. S2).
Table 1. Hematologic parameters of C57BL/6 mice treated
for 14 days with saline (0.9%) or FA (4 mg/kg/day).
Blood parameter
Saline
(n=10)
FA-treated
(n=10) P value
RBC, 610
6/mL 9.3260.7 7.4560.09 ,0.001*
Hematocrit, % 44.063.5 36.064.4 ,0.005*
Hemoglobin, g/dL 14.761.08 11.661.0 ,0.001*
MCV, fL 47.2460.71 48.4960.7 0.01*
MCHC, g/dL 33.662.76 32.4163.10 0.38
Platelets, 610
3/mL 804684 73467.3 0.067
Neutrophils, 610
3/mL 1.2860.3 0.8960.4 0.02*
RBC indicates Red Blood Cell; MCV, Mean Corpuscular Volume; MCHC, Mean
Corpuscular Hemoglobin Concentration.
Data are presented as mean 6 SD.
*significantly different from value for saline-treated mice.
doi:10.1371/journal.pone.0023850.t001
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challenge
Erythropoiesis can increase dramatically in response to acute
anemia. To determine whether aconitase inhibition interferes with
the capacity to respond to anemic challenge, mice treated with
saline or 4 mg/kg/day FA received intraperitoneal injections of
the hemolytic agent phenylhydrazine (PHZ) with dosage reduction
made for the FA-treated group to prevent lethality (see Materials
and Methods). PHZ treatment typically leads to an RBC nadir on
day 3 post-injection followed by complete recovery on day 7 [31].
Despite receiving half the standard PHZ dose, mice treated with
FA developed an anemia that was much more pronounced and
prolonged than that of the control mice. Specifically, their RBC
counts reached nadir on day 7 instead of day 3 and did not return
Figure 1. In vivo effects of aconitase inhibition. (A) Serum EPO levels in mice treated for 14 days with an infusion of saline (0.9%) or FA (4 mg/
kg/day). Data represent mean 6 SD; n=9 for saline group and 10 for FA group;
{ P,0.001. (B) Absolute reticulocyte counts in mice treated as in
panel A. Data represent mean 6 SD; n=10 per group;
{ P,0.001. (C) Erythroid maturation in marrows from mice who received a four-week infusion
of FA (2 mg/kg/day) or saline (0.9%). Representative flow cytometry plots are shown. Boxes indicate erythroid developmental stages R1–R4, from top
left (R1) to bottom right (R4). (D), (E) Summary of data from panel C displayed as cell percentages (D) or absolute cell numbers per femur (E)i n
regions R1–R4. Data is presented as mean 6 SD; n=4 per group;
* P,0.05.
doi:10.1371/journal.pone.0023850.g001
Regulation of Erythropoiesis by Aconitase Enzymes
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23850to baseline even 17 days after PHZ administration (Fig. 2A). In
addition, their reticulocyte response was delayed and diminished
(Fig. 2B).
Further characterization of the role of aconitase in the response
to acute anemia employed mice lacking cytosolic aconitase
(IRP12/2 mice) [32]. These mice, along with wild-type aged-
matched controls, received standard doses of PHZ and were
monitored for responsiveness. As shown in Figs. 2C and 2D,
IRP12/2 mice responded to PHZ-induced anemia in a manner
indistinguishable from wild type mice. The starting RBC counts,
the magnitude of their decrease, and the rate of recovery were not
significantly different in the two groups; both also exhibited a
similar reticulocyte response during the recovery phase. These
results indicate that cytosolic aconitase is dispensable for both
steady-state erythropoiesis and for responsiveness to acute anemia
(see Discussion).
Aconitase inhibition affects erythropoiesis in a cell-
intrinsic manner
The in vivo effects of FA infusion support a role for aconitase
activity in the regulation of erythropoiesis but could also reflect
indirect influences mediated by the marrow microenvironment.
Therefore, ex vivo primary cultures were used to examine the
effects of aconitase inhibition directly on erythropoiesis. In these
experiments, purified human CD34
+ cells were cultured in
unilineage erythroid medium (see Materials and Methods) with
or without fluoroacetate. Aconitase inhibition caused a dose-
dependent decrease in proliferation over a five day culture period,
with 10 mM causing a statistically significant decrease and 100 mM
abrogating growth altogether (Fig. 3A). The proliferation defect
was not secondary to cell death, as FA treatment had minimal
effects on overall viability and no effects on apoptotic signaling
(Figs. 3B,C). All subsequent experiments employed 50 mMF A
because this dose reproducibly inhibited proliferation and
maturation (see below) without affecting viability. In addition,
this dose strongly inhibited aconitase activity in erythroid
progenitors, causing a 10-fold increase in intracellular citrate
levels (Fig. S3).
Erythroid differentiation was assessed by examining the
expression of two developmental markers: CD34, a stem cell
antigen rapidly downregulated after the early burst forming unit-
erythroid (BFU-E) stage, and glycophorin A (GPA), an erythroid-
specific antigen appearing initially at the proerythroblastic stage
and continually increasing with differentiation [33,34]. Addition of
FA to the erythroid cultures impaired the downregulation of CD34
while attenuating the upregulation of GPA (Fig. 3D). Specifically,
FA treatment caused a 5-fold increase in the frequency of cells
coexpressing CD34 and GPA, two markers that minimally overlap
during normal maturation (Fig. 3E). These results demonstrate
cell-intrinsic defects in proliferation and maturation associated
with aconitase inhibition in cultured erythroid progenitors.
The effects of aconitase inhibition on erythropoiesis
occur independently of metabolic impairment
To determine whether the defect in erythropoiesis caused by
aconitase inhibition occurred secondary to alterations in Krebs
Figure 2. Inhibition of aconitase impairs responsiveness to anemic challenge. (A) RBC and (B) absolute reticulocyte counts in PHZ-
challenged mice treated with either FA (4 mg/kg/day; n=11) or saline (0.9%; n=6). PHZ injections on days 0 and 1 consisted of 30 mg/kg/day for the
FA group and 60 mg/kg/day for the saline group. Data represent mean 6 SD. (C) RBC and (D) absolute reticulocyte counts in IRP12/2 and wild type
(WT) mice. PHZ doses for both groups consisted of 60 mg/kg/day on days 0 and 1. Data represent mean 6 SD; n=8 per group.
doi:10.1371/journal.pone.0023850.g002
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ters were assessed. Firstly, 50 mM FA had no effect on cellular
steady state ATP levels in day 5 erythroid cultures (Fig. 4A).
Secondly, FA treatment did not alter the activation status of AMP-
kinase (AMPK) (Fig. 4B). AMPK functions as a sensor of the
AMP:ATP ratio; an increase in this ratio activates AMPK, which
in turn upregulates catabolic pathways to restore cellular ATP
levels [35]. Thirdly, the FA treatment did not alter levels of
reactive oxygen species (ROS), as detected by the fluorescent
indicator 39-(aminophenyl)-fluorescein (APF) [36]. APF mean
fluorescence intensity (MFI) was identical in untreated and FA-
treated erythroid cultures, both in early (GPA negative gate) and
late progenitors (GPA positive gate) (Fig. 4C). Fourthly, 50 mMF A
did not alter the mitochondrial membrane potential (MMP), as
assessed by staining with the membrane permeant dye Mito-
Tracker CMXRos [37]. In both early (GPA negative) and more
Figure 3. Effects of aconitase inhibition on erythroid proliferation, survival and maturation in vitro. (A) Fold increase in number of
primary human progenitors cultured for five days in erythroid medium with the indicated doses of FA. Shown are mean 6 SD for three independent
experiments;
* P,0.05;
{ P,0.01. (B) Survival of cells from day 5 erythroid cultures 650 mM FA assessed by staining with 7-amino actinomycin D (7-
AAD) and annexin V-PE followed by flow cytometry; numbers indicate percentages of cells in each quadrant. (C) Apoptotic signaling in cells from day
5 erythroid cultures with 0, 10, 50, and 100 mM FA assessed by immunoblotting of whole cell lysates for caspase-3 (arrow indicates position of
cleavage product). (D) Differentiation of erythroid progenitors cultured as in panel B. Surface expression of CD34 and GPA was assessed by flow
cytometry on live cells; numbers indicate percentages of cells in each quadrant. (E) Multiple independent experiments as in panel D show an increase
in the percentage of CD34
+ GPA
+ cells associated with FA treatment. Shown are mean 6 SD; n=6;
{ P,0.001.
doi:10.1371/journal.pone.0023850.g003
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staining was unaffected by FA treatment (Fig. 4D). These results
demonstrate that the degree of aconitase inhibition sufficient to
impair erythropoiesis is below the threshold that disrupts cellular
ATP levels, redox status, or MMP.
Aconitase modulates ERK signaling downstream of EPO
Several studies have identified non-metabolic functions for
aconitase, including participation in signaling modules [4,7,9].
Therefore experiments addressed whether aconitase inhibition
affected the activation state of EPO-dependent signaling pathways.
Immunoblotting with phospho-specific antibodies on whole cell
lysates from erythroid cultures showed no effects of FA on basal
signaling via JAK2-STAT5, calcineurin-NFAT, PI3K-Akt, PKCa/
bII, and PLCc pathways (data not shown) [38–42]. However,
aconitase inhibition correlated with increased steady state levels of
phosphorylated ERK (Fig. 5A). Unexpectedly, this increase in
phospho-ERK was accompanied by a decrease in phosphorylation
Figure 4. FA inhibits erythropoiesis in the absence of changes in cellular ATP, ROS, or MMP. (A) ATP levels in cells from day 5 erythroid
cultures of human CD34
+ progenitors treated with 0–100 mM FA. Shown are values relative to untreated cultures consisting of mean 6 SD from three
independent experiments. (B) APMK activation in cells from day 5 erythroid cultures with 0–100 mM FA assessed by immunoblotting of whole cell
lysates for phospho- and total AMPK. (C) Levels of reactive oxygen species (ROS) in cells from day 3 erythroid cultures 650 mM FA detected by the
fluorescent probe APF. Mean fluorescence intensities (Geom. Mean) of the APF signal within GPA-negative and positive gates are shown adjacent to
flow cytometry plots. (D) Mitochondrial membrane potential in cells from day 3 erythroid cultures 650 mM FA detected by MitoTracker CMXRos.
Mean fluorescence intensities (Geom. Mean) of the MitoTracker signal within GPA-negative and positive gates are shown adjacent to flow cytometry
plots.
doi:10.1371/journal.pone.0023850.g004
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phosphorylation of ERK and RSK as determined by immunoblotting of whole cell lysates of cells from days 3–4 erythroid cultures treated with 50 mMF Aa n d
10 mM U0126 as indicated (NT, untreated). (B) Time course of ERK1/2 and RSK phosphorylation. Cells from day 3 erythroid cultures 650 mM FA were subjected
to 3 hours of cytokine starvation followed by stimulation with 4.5 U/ml EPO for the indicated time periods. (C) EPO induction of multiple downstream
pathways in cells treated as in panel B.( D) Densitometric analysis of pERK1/2:ERK1/2 and pRSK:RSK levels in five independent experiments conducted as in
panel C. Presented are mean values 6 SEM for relative phosphoprotein signal divided by total protein signal; * P,0.05;
{ P,0.01; n.s., not significant.
doi:10.1371/journal.pone.0023850.g005
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threonine 573 [43]. The requirement of MEK-ERK signaling for
RSK T573 phosphorylation was confirmed by treatment of cells
with the MEK inhibitor U0126 (Fig. 5A).
To characterize the effects of aconitase inhibition on the
initiation of EPO signaling, erythroid progenitors pre-cultured
with or without FA underwent cytokine starvation followed by
acute stimulation with EPO. FA treatment did not prevent EPO
activation of ERK but almost completely blocked its activation of
RSK (Fig. 5B). In control cells treated with EPO, phospho-ERK
levels peaked at 10 minutes, and phospho-RSK levels peaked at
15 minutes (Fig. 5B). In the FA treated cells, EPO induction of
phospho-ERK also peaked at 10 minutes, but phospho-RSK
showed no increase over the entire 1 hour time course. These
signaling abnormalities were consistently observed in multiple
independent experiments (Fig. 5D). By contrast, FA pretreatment
had no effect on EPO induction of STAT5 or Akt activation
(Fig. 5C). The data from steady state erythroid cultures and from
EPO stimulation of cytokine-starved cells thus show that aconitase
inhibition interferes with ERK-mediated activation of RSK.
MEK inhibition recapitulates the effects of aconitase
inhibition on erythropoiesis
To determine whether impaired ERK signaling might underlie
the erythroid defects associated with aconitase inhibition, FA and
the MEK inhibitor U0126 were compared for their effects on
erythropoiesis as in Figure 3. The MEK inhibitor at 10 mM
reproducibly inhibited proliferation to the same degree as 50 mM
FA (Fig. 6A), and both agents yielded similar cell cycle
perturbations on propidium iodide staining, i.e. increased cells in
G0/G1 (Figs. 6B,C). MEK inhibition also impaired erythroid
differentiation in a manner similar to aconitase inhibition,
characterized by the accumulation of an aberrant CD34
+ GPA
+
double positive population (Fig. 6D). As with aconitase inhibition,
MEK inhibition minimally affected cell viability (Fig. 6E). The
similar phenotypic effects resulting from FA and U0126 treatments
thus support the notion that aconitase and ERK signaling
participate in a common erythroid regulatory pathway.
An aconitase-ERK protein complex that is disrupted by
aconitase inhibition
Large scale proteomic mapping of interaction networks in
Saccharomyces cerevisiae has shown mitochondrial aconitase to
interact with ,20–30 partner proteins, of which one is KSS1, a
yeast homolog of ERK; reciprocal analysis of KSS1 also identified
aco1 (yeast mitochondrial aconitase) as an interaction partner
[44]. Furthermore, high stringency scanning for motifs using
Scansite 2.0 predicts ERK Docking Domains (D-Domains) in both
aconitase isoforms [45]. To test for interaction between aconitase
enzymes and ERK in a mammalian system, immunoprecipitation
was conducted on epitope-tagged proteins co-expressed in
HEK293T cells cultured under a variety of conditions, including
FA and EGF treatment. Higher FA doses were used in these
experiments due to the relative resistance of HEK293T cells to the
growth inhibitory effects of FA, most likely related to high levels of
endogenous aconitases. ERK bound both aconitase isoforms,
showing a stronger interaction with mitochondrial aconitase
(Fig. 7A). FA treatment potently and reproducibly diminished
ERK2 interaction with mitochondrial aconitase. ERK activation
by EGF treatment of serum-starved cells did not significantly affect
the interaction, nor did mutation of the D-domain binding site in
ERK2 (D319N) (Fig. 7B) [46]. ERK1 was also found to interact
with mitochondrial aconitase (data not shown). Our data thus
confirm an interaction of mitochondrial aconitase with ERK1/2,
reinforcing previous findings in Saccharomyces cerevisiae. This
interaction is disrupted by inhibition of aconitase activity but does
not appear to depend on ERK activation or D-domain
recognition.
Activation of cytoplasmic ERK targets such as RSK has been
shown to depend on dimerization of ERK monomers [47].
Dimerization occurs in response to mitogenic stimuli, such as EGF
in HEK293T cells, and provides a mechanism to spatially regulate
ERK signaling. To test whether interaction with aconitase
regulates ERK dimer formation, HEK293T cells 6 FA and
EGF were subjected to ERK2 dimer detection according to the
method of Casar et al [47]. FA treatment had no effect on ERK2
dimer formation (Fig. S4), arguing against a role for aconitase in
regulating ERK dimerization.
Low dose aconitase inhibition normalizes red cell counts
in a mouse model of polycythemia vera
To determine whether aconitase inhibition could provide a
therapeutic strategy for lowering red cell mass in polycythemia
vera, we treated C57BL/6 mice expressing a human mutant
JAK2V617F transgene (PV mice) and wild type (WT) littermate
controls with a low dose infusion of FA (2 mg/kg/day) [48].
Mock-treated PV mice had significantly elevated red cell counts
compared with normal controls (10.4–10.7610
6/ml in PV vs. 8.4–
8.7610
6/ml in WT) (Fig. 8A). FA infusion normalized the RBC
counts in PV mice after seven days and stably maintained these
counts in the normal range for the duration of treatment (Fig. 8A).
Platelet, neutrophil, and lymphocyte counts were not affected by
FA treatment (Table S2). In PV marrows, as previously seen in
WT marrows, FA increased the proportion of R3 erythroid
precursors. A significant decrease in the percentage of more
mature R4 precursors was also observed (Figs. 8B,C). These results
suggest that a minor degree of aconitase inhibition in vivo may
suffice to achieve clinically significant reductions in red cell mass in
polycythemia vera.
To determine effects of aconitase inhibition on signaling by the
constitutively active mutant JAK2V617F, Ba/F3 transfectants
expressing EPOR 6 JAK2V617F [49,50] underwent treatment
with FA. These cells however were resistant to growth inhibition
by FA doses 20-fold higher than those effective on primary
erythroid progenitors (Fig. S5). As an additional complication, the
Ba/F3 EPOR JAK2V617F cells showed a paradoxical response to
EPO stimulation consisting of marked downregulation of RSK
phosphorylation (Fig. S6).
Discussion
Inactivation of aconitase enzymes contributes to the erythroid
response to iron restriction [4]. However, because iron deprivation
simultaneously affects multiple signaling and metabolic pathways,
the exact role of aconitases in erythropoietic regulation has
remained unclear. The current studies have directly examined the
role of aconitases during erythroid development by use of a specific
active site inhibitor. Application of this approach has confirmed
that aconitase activity potently regulates erythropoiesis in vivo and
in vitro. In vivo, aconitase inhibition caused a rapid-onset
hypoplastic anemia with slightly macrocytic, normochromic red
cells (Table 1). These red cell features suggest that the anemia did
not arise from impaired production of heme due to deficiency of
succinyl CoA. Anemias caused by defective heme synthesis, such
as those due to deficiencies of erythroid-specific d-aminolevulinate
synthase or ferrochelatase, are characteristically microcytic and
hypochromic [51,52]. The low reticulocyte counts combined with
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23850Figure 6. The effects of MEK inhibition on erythropoiesis recapitulate those of aconitase inhibition. (A) Fold increase in number of
primary progenitors cultured for 3 days with either 50 mMF Ao r1 0mM U0126. Shown are mean 6 SD for three independent experiments;
{ P,0.01.
(B) Cell cycle profiles of cells from day 3 cultures as in panel A determined by propidium iodide staining followed by flow cytometry. Percentages of
cells in G0/G1, S, and G2/M phases are indicated. (C) Multiple independent experiments as in panel B showing an increase in the percentage of cells in
G0/G1 associated with either FA or U0126 treatment. Data represent mean 6 SD; n=3;
{ P,0.01. (D) Erythroid differentiation of progenitors cultured
as in panel A assessed by staining for GPA and CD34 followed by flow cytometry; percentages of cells in each quadrant are shown. (E) Viable fractions
from panel D determined by forward (FSC) and side (SSC) light scatter properties.
doi:10.1371/journal.pone.0023850.g006
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interfered with red cell production, a conclusion further supported
by the poor reticulocyte response to phenylhydrazine challenge
seen in FA-treated animals (Fig. 2B). Furthermore, in vivo and in
vitro studies both showed impaired differentiation of erythroid
progenitors associated with aconitase inhibition (Figs. 1C, 3D, 8B).
Figure 7. Identification of an ERK-aconitase protein complex that is disrupted by aconitase inhibition. (A) Assessment of ERK-aconitase
interactions by coexpression followed by coimmunoprecipitation. ERK2 and FLAG-tagged cytosolic aconitase (cAcon-FLAG) or mitochondrial
aconitase (mAcon-FLAG) were coexpressed in HEK293T cells 6500 mM FA. Immunoprecipitation (IP) with FLAG beads was followed by
immunoblotting (IB) for total ERK and for the FLAG epitope. (B) Role of ERK D-domain interacting motif in ERK2 binding to mitochondrial aconitase.
mAcon-FLAG was coexpressed with ERK2 WT or D319N in HEK293T cells 6500 mM FA, 6100 ng/ml EGF, followed by IP and IB as in panel A.
doi:10.1371/journal.pone.0023850.g007
Figure 8. Aconitase inhibition normalizes red cell counts in a murine model of polycythemia vera. (A) RBC values over the course of a
four-week infusion of saline (0.9%; n=3) or FA (2 mg/kg/day; n=10). Data represent mean 6 SD. (B) Erythroid maturation in day 28 PV marrows.
Boxes indicate erythroid developmental stages R1–R4. (C) Summary of data from panel B with mean percentages of cells in R1–R4 6 SD; n=3 per
group;
* P,0.05;
{ P,0.01.
doi:10.1371/journal.pone.0023850.g008
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aconitases to erythroid regulation will require development of
new conditional knockout mice with individual and compound
gene deletions. Several lines of evidence, however, suggest that
mitochondrial aconitase plays a key role. Firstly, fluoroacetate acts
predominantly as an inhibitor of mitochondrial aconitase, based
on the location of its enzymatic conversion to fluorocitrate, the
active inhibitor [53]. Secondly, infusion of FA in mice lacking
cytosolic aconitase (IRP12/2) induced an anemia identical to
that occurring in wild-type mice (Fig. S7). Thirdly, IRP12/2
mice showed no hematologic defects in response to anemic
challenge (Figs. 2C,D). Fourthly, mitochondrial aconitase bound
ERK more avidly than cytosolic aconitase and, unlike its cytosolic
counterpart, displayed modulation of ERK binding by FA (Fig. 7).
Several studies have previously demonstrated mitochondrial
regulation of erythroid differentiation and proliferation. For
example, the inhibition of mitochondrial biogenesis by chloram-
phenicol is associated with impaired erythropoiesis in vivo and in
vitro [54,55]. The ability of exogenous isocitrate to reverse in vitro
differentiation defects caused by chloramphenicol has suggested
that mitochondrial aconitase may participate in the regulation of
erythropoiesis by mitochondrial function [4]. Further supporting
this notion, multiple murine models of impaired mitochondrial
function all show a similar, distinctive erythroid maturation defect,
i.e. an increase in CD71
Intermediate Ter119
Bright progenitors (R3
stage), closely resembling the defect seen with FA infusion (Figs. 1C
and 8B) [56–58].
Among the various pathways downstream of EPO regulating
erythroid development, only the ERK pathway displayed
consistent modulation in response to aconitase inhibition. In
particular, FA treatment diminished RSK T573 phosphorylation
in erythroid progenitors subjected to either acute or chronic EPO
stimulation (Fig. 5). The effects of aconitase inhibition on ERK
signaling are likely to be biologically relevant because direct
inhibition of ERK activation with the MEK inhibitor U0126
recapitulated several key features of the erythroid response to FA
(Fig. 6). By contrast, our data suggest that the effects of FA were
unrelated to changes in ATP, ROS, or mitochondrial membrane
potential (Fig. 4). Why FA had no effect on these latter parameters
may be related to the dose employed, to possible metabolic
compensation by cytosolic aconitase, or to the dependence of early
hematopoietic progenitors more on glycolysis than on oxidative
phosphorylation.
The mechanism underlying the cross-talk between aconitase
and ERK, while unclear, may relate to the assembly of protein
complexes containing ERK and mitochondrial aconitase (Fig. 7).
Interestingly, such complexes are phylogenetically conserved back
to yeast and are regulated by aconitase activity. Previous studies
have documented localization of ERK in mitochondria
[20,59,60]. Whether mitochondrial aconitase participates in an
organelle-specific ERK scaffolding complex, as has been described
for endosomes and Golgi [17,18], remains a subject of
investigation. Nevertheless, the current studies provide a novel
function for aconitase as a licensing factor for erythropoietin-
dependent transduction of ERK signaling. This regulatory input
could permit adjustment of ERK activity in accordance with
aconitase function, which in turn is affected by iron availability,
redox, and iron-sulfur cluster assembly pathways. In this manner,
a variety of signals reflecting mitochondrial status potentially could
be transmitted to the machinery driving proliferation and
differentiation.
The ability to modulate red cell production with low dose
aconitase inhibition may have therapeutic implications for
polycythemia vera. Phlebotomy, the primary treatment for this
disease, controls red cell mass via induction of iron deficiency,
most likely acting through erythroid inactivation of aconitase.
Attainment of iron deficiency may require numerous blood draws
over a prolonged period and may be complicated by significant
thrombocytosis [61]. Repeated phlebotomy also poses a risk for
phlebitis and infection. In a mouse model of JAK2 V617F-driven
polycythemia, low dose aconitase inhibition rapidly normalized
red cell counts in a lineage specific manner without causing
anemia (Fig. 8, Table S2). However, further studies are needed to
determine the clinical feasibility of this approach. Fluoroacetate is
a known toxic agent that targets the cardiovascular and central
nervous systems in mice and humans. Reported lethal doses range
from 0.5 to 19 mg/kg in mice and 2 to 10 mg/kg in humans [62].
While a continuous FA infusion of 2 mg/kg/day corrects red cell
counts in PV mice in the absence of overt symptoms, toxicology
studies will be necessary to rule out adverse effects of both acute
and chronic administration.
Materials and Methods
Mice
PV mice consisted of line A JAK2V617F transgenic mice
between the ages of 10 and 14 weeks [48]. IRP12/2 mice were
generously donated by Dr. Tracey Rouault (National Institute of
Child Health & Human Development, Bethesda, MD) [32].
Animal studies were approved by the University of Virginia
Animal Care and Use Committee (ACUC, protocol 3545, latest
annual renewal approved on 6.15.10). Mice were housed in a
pathogen-free facility and handled in accordance with the policies
of the University of Virginia ACUC. For continuous in vivo
infusions, a sterile 0.9% saline solution or sodium fluoroacetate
(FA) solution prepared in 0.9% saline was delivered subcutane-
ously using Alzet osmotic pumps model 1002 or 1004 (Durect,
Cupertino, CA) based on the approach of Isken and colleagues
[28]. Phenylhydrazine (Sigma, St. Louis, MO) prepared in sterile
phosphate-buffered saline (PBS) was administered by intraperito-
neal bolus injection at doses of 30 mg/kg/day62 days (FA-treated
mice) or 60 mg/kg/day62 days (saline-treated mice). Blood was
collected from the retro-orbital plexus into EDTA-coated micro
tubes (BD Biosciences, Franklin Lakes, NJ) using heparinized
micro-capillary tubes. Complete blood counts were measured on a
Hemavet 850FS automated analyzer (Drew Scientific, Dallas,
TX). Serum EPO levels were determined with the Quantikine
Mouse EPO ELISA kit (R&D Systems, Minneapolis, MN).
Cell culture
Peripheral blood mobilized, purified human CD34
+ cells were
obtained from the Hematopoietic Cell Processing Core at the Fred
Hutchinson Cancer Center (Seattle, WA) as previously described
[4]. After 72 hours in multi-lineage serum-free medium, the cells
were seeded in serum-free erythroid differentiation medium
consisting of Iscove’s modified Dulbecco medium (IMDM)
supplemented with 4.5 U/ml EPO (Amgen, Thousand Oaks,
CA), 25 ng/ml stem cell factor (PeproTech, Rocky Hill, NJ),
bovine serum albumin (BSA, Sigma), and 100% Fe-saturated
transferrin (Stem Cell Technologies, Vancouver, Canada) [4].
Sodium fluoroacetate was purchased from Sigma, and U0126
from Cell Signaling Technology (Beverly, MA). For cytokine
starvation experiments, cells that had been cultured in erythroid
medium for 72 hours were washed in PBS and re-suspended in
IMDM supplemented with 0.1% BSA for 3 hours, followed by
stimulation with 4.5 U/ml EPO. Murine Ba/F3 EPOR and Ba/
F3 EPOR JAK2V617F cell lines have been previously described
[63]. Both cells lines were maintained in Roswell Park Memorial
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serum (Invitrogen, Carlsbad, CA) and 2 ng/ml murine IL-3
(PreproTech). For cytokine starvation experiments, cells were
washed twice in RPMI and cultured for 4 hours in RPMI prior to
stimulation with 10 U/ml EPO (Amgen).
Plasmids and transfections
pcDNA3-HA-ERK2 wt and D319N, as well as pcDNA3-T7-
ERK1, were purchased from Addgene (Cambridge, MA). Full-
length cDNAs for human ACO1 (encoding cytosolic aconitase) and
ACO2 (encoding mitochondrial aconitase) (Open Biosystems,
Huntsville, AL) were subcloned into the XhoI and NotI sites of
pCMV Tag4A (Stratagene, La Jolla, CA) to express mAcon-
FLAG and cAcon-FLAG. A 39 SalI, rather than XhoI, site was
introduced into the ACO2 insert. Transient transfections in
HEK293T cells were carried out using the calcium phosphate
method, as previously described [64]. Cells were serum-started for
6 hours, followed by stimulation with 100 ng/ml epidermal
growth factor (EGF, PeproTech) for 5 minutes prior to harvest
where indicated. 36 hours post-transfection, cells were resus-
pended in NP-40 extraction buffer containing 50 mM Tris-HCl
(pH 7.6), 150 mM NaCl, 0.5% NP-40, 1 mM MgCl2,5 0 mM
ZnSO4, EDTA-free protease inhibitor cocktail (Roche, Indianap-
olis, IN), 1 mM sodium orthovanadate and 10 mM sodium
fluoride. Following a 20 minute incubation at 4uC, insoluble
debris was removed by centrifugation.
Immunoblot and immunoprecipitation
Western blot analysis was performed as previously described
after sodium dodecyl sulfate-poly-acrylamide gel electrophoresis
(SDS-PAGE) [65]. Antibodies to phospho-ERK1/2 (T202/Y204),
ERK1/2, RSK1, phospho-STAT5 (Y694), STAT5, phospho-Akt
(S473), Akt, AMPK, and phospho-AMPK (T172) were purchased
from Cell Signaling Technology. Anti-phospho-RSK (T573) was
purchased from Epitomics (Burlingame, CA); anti-caspase 3 from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-tubulin and
anti-actin were purchased from Sigma. Immunoprecipitation of
aconitase-containing complexes was performed by incubating
cellular extracts with M2 agarose FLAG beads (Sigma) for 2 hours
at 4uC. Following washing of beads, proteins eluted in SDS-PAGE
loading buffer underwent SDS-PAGE and immunoblot analysis
using antibodies to ERK1/2 (Cell Signaling Technology) and
FLAG (Sigma). Densitometry data were acquired on a GS800
calibrated densitometer (Bio-Rad, Hercules, CA) and analyzed
with the Quantity One software (Bio-Rad). For ERK2 dimer
formation analysis, HEK293T cells were serum-starved overnight
6500 mM FA and stimulated with 100 ng/ml EGF for 5 minutes
prior to harvest and analysis by native gel electrophoresis as
described [66].
Flow cytometry
Cells were analyzed on a FACSCalibur instrument (Becton
Dickinson, San Jose, CA). All fluorochrome-conjugated antibodies
were purchased from BD Pharmingen (San Diego, CA), with the
exception of PE-anti-CD71 (Dako, Carpinteria, CA). Erythroid
differentiation was assessed by co-staining human erythroid
progenitors with fluorochrome-conjugated antibodies to GPA
(FITC or PE), CD71 (PE), CD34 (APC), and CD44 (FITC).
Reticulocytes were measured by staining whole blood with
thiazole orange as described [67]. Bone marrows were harvested
from femurs into PBS supplemented with 5 mM EDTA and
stained with APC-anti-Ter119 and PE-anti-CD71. Cell death was
analyzed with the Annexin V-PE Apoptosis Detection Kit I (BD
Pharmingen). For cell cycle analysis, cells underwent ethanol
fixation and RNase A treatment followed by propidium iodide
staining. Data was analyzed using the FlowJo software (version
8.6.3, TreeStar Inc., Ashland, OR).
Metabolic assays
Citrate measurements were performed using the BioVision
Citrate Assay kit according to the manufacturer’s instructions
(BioVision, Mountain View, CA). To measure intracellular levels,
metabolic extracts from day 5 untreated and 50 mM FA-treated
CD34
+ erythroid cultures were obtained as previously described
[4]. Fluorimetry was performed on a FluoSTAR Optima
fluorescent microplate reader (BMG Labtech, Cary, NC) and
analyzed with the MARS data analysis software (version 1.01,
BMG Labtech). To measure serum citrate, whole blood was
collected retro-orbitally and allowed to clot at room temperature
for 30 minutes. Clotted samples were centrifuged at 13,000 g for
5 minutes at room temperature and sera were stored at 220uC.
Samples were deproteinized using the Deproteinization Sample
Preparation kit (BioVision) according to the manufacturer’s
instructions.
ATP measurements were performed as described [4]. Staining
of cells with 39-(aminophenyl)-fluorescein (APF) followed the
manufacturer’s guidelines (Invitrogen). Briefly, CD34 cells
650 mM FA were stained with APC-anti-GPA (BD Pharmingen)
and APF, and mean fluorescence intensity of the APF dye was
determined by flow cytometry after gating on GPA-negative and
positive populations. Mitochondrial membrane potential was
determined by staining cells with MitoTracker Red CMXRos
dye (Invitrogen) according to the manufacturer’s instructions,
followed by staining for GPA. The mean fluorescence intensity of
MitoTracker stained cells was determined by flow cytometry after
gating on GPA-negative and positive populations.
Statistical analysis
GraphPad Prism software version 5.01 (GraphPad Software,
Inc., La Jolla, CA) was used to display the data graphically and to
perform statistical analysis. Results were analyzed by unpaired
two-tailed Student’s t test or one-way analysis of variance
(ANOVA) with Newman-Keuls post-test when comparing multi-
ple groups. P values less than or equal to 0.05 were considered
significant.
Supporting Information
Figure S1 Elevated serum citrate levels in mice treated
with fluoroacetate. Sera from saline-treated and FA-treated
(2 mg/kg/day) mice were isolated from whole blood collected on
day 26 post initiation of treatment. Citrate levels were determined
enzymatically. Data are presented as mean 6 SD; n=8 per group;
{ P,0.001.
(TIF)
Figure S2 Analysis of the bone marrow erythroid
maturation using Ter119 and CD44. (A) Erythroid matura-
tion in marrows from mice who received a four-week infusion of
FA (2 mg/kg/day) or saline (0.9%). After gating on the Ter119
+
fraction, cells were analyzed for CD44 expression versus Forward
Scatter (FSC). Representative flow cytometry plots are shown.
Roman numerals I-V indicate distinct erythroid subpopulations.
(B) Summary of data from panel A with mean percentages of cells
in subpopulations I-V 6 SD; n=4 per group;
* P,0.05. (C)
Summary of data from panel A with absolute number of cells per
femur in subpopulations I-V 6 SD; n=4 per group;
{ P,0.01.
(TIF)
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cells. CD34
+ cells were cultured in erythroid medium for 5
days650 mM FA. Cellular extracts were assayed for citrate levels
enzymatically. Data are presented as mean fold increase over
control cells 6 SD; n=4;
{ P,0.01.
(TIF)
Figure S4 Aconitase inhibition does not prevent ERK
dimerization. Detection of ERK2 dimer formation upon EGF
stimulation by native gel electrophoresis followed by immunoblot-
ting. HEK293T cells 6500 mM FA, 610 mM U0126 were
cytokine-starved overnight and stimulated with 100 ng/ml EGF
for 5 minutes prior to harvest.
(TIF)
Figure S5 Ba/F3 cells expressing EPOR or EPOR plus
JAK2V617F are relatively resistant to the growth inhib-
itory effects of FA. (A) Proliferation of Ba/F3 EPOR cells
cultured in the presence of 2 ng/ml murine IL-3 and treated with
0–5 mM FA for 72 hours. Data are presented as mean 6 SD;
n=3; * P,0.05; n.s., not significant. (B) Proliferation of Ba/F3
EPOR JAK2V617F cells cultured as in panel A. Data are
presented as mean 6 SD; n=3;
{ P,0.01.
(TIF)
Figure S6 Paradoxical RSK deactivation in Ba/F3 EPOR
JAK2V617F cells in response to EPO stimulation. Ba/F3
EPOR and Ba/F3 EPOR JAK2V617F cells were starved of
cytokines for four hours prior to stimulation with 10 U/ml EPO
for ten minutes. Phosphorylation of ERK and RSK was assessed
by immunoblotting of whole cell lysates.
(TIF)
Figure S7 Mice lacking cytosolic aconitase respond
normally to fluoroacetate infusion. (A) RBC and hematocrit
values in WT, IRP1+/2 and IRP12/2 mice treated for 23 days
with (2 mg/kg/day). Data represent mean 6 SD; n=6 per group.
(B) Absolute reticulocyte counts in the WT, IRP1-/WT and
IRP12/2 groups, as in panel A.( C) Erythroid maturation in
marrows from FA-treated animals. Representative flow cytometry
plots are shown. Boxes indicate erythroid developmental stages
R1–R4. (D) Summary of results from panel C showing mean
percentages of cells in R1–R4 6 SD; n=3 per group.
(TIF)
Table S1 CBC parameters of WT mice treated for four weeks
with saline (0.9%) or FA (2 mg/kg/day).
(DOC)
Table S2 CBC parameters of PV mice treated for four weeks
with saline (0.9%) or FA (2 mg/kg/day).
(DOC)
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